Accendra Health, Inc. · NYSE:ACH
Accendra Health — Q3 2026 Earnings Presentation
13 slides from Accendra Health's earnings presentation, Nov 5, 2026
Slide 1: Third Quarter 2026 Continuing Operations Supplemental Slides
Third Quarter 2026 Continuing Operations Supplemental Slides November 5, 2026
Slide 2: Safe Harbor
Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This presentation contains certain “forward looking” statements made pursuant to the S
Slide 3: Non-GAAP
Non-GAAP This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect the Company’s core business and relate more to strat
Slide 4: About Accendra Health
About Accendra Health • Accendra Health, Inc. is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. • We connect patients, providers, and insurers, delivering innovative solutions that help promote better heal
Slide 5: Accendra Health At A Glance
Accendra Health At A Glance Business Highlights ~$2.5B ~2.9 million ~2,500 • Pure-Play Patient Direct Leader Commercial Payor • Scaled Chronic Focused Portfolio Revenue Active Patients Contracts • National Footprint and Scale • Broad Payor Access and Reach Diverse Mix Across Equipment Product Catego
Slide 6: Net Revenue Supplemental Information
$ millions Net Revenue Supplemental Information $697 $(88) $10 $602 $(6) $6 $(5) $(6) $(6) p. 6
Slide 7: Adjusted EBITDA Supplemental Information
$ millions Adjusted EBITDA Supplemental Information(1) $92 $(20) $(4) $(1) $(13) $48 $(6) Large Commercial Payor Net of Manufacturer Cost Increases Collection Rate Q3 2025 Actual Cost Reductions Volume Inflation & Other Q3 2026 Actual (1) Adjusted EBITDA is a non-GAAP financial measure a reconciliat
Slide 8: Q3 & YTD 2026 Adjusted EBITDA and Free Cash Flow
Q3 & YTD 2026 Adjusted EBITDA and Free Cash Flow $ millions Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 Loss from continuing operations, net of tax, as reported (GAAP) $ (18) $ (113) Income tax (benefit) (19) (27) Interest expense, net 38 105 Acquisition-related charge
Slide 9: Cash Flow Supplemental Information
Cash Flow Supplemental Information In millions Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 Loss from continuing operations, net of tax, as reported (GAAP) $ (18) $ (113) Income tax benefit (19) (27) Interest expense, net 38 105 Acquisition-related charges and intangibl
Slide 10: Cash Flow Supplemental Information, continued
Cash Flow Supplemental Information, continued The following are presented as reconciling items on the Cash Flow supplemental information slide: 1) Acquisition-related charges and intangible amortization includes amortization of intangible assets established during acquisition method of accounting fo
Slide 11: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Three Months Ended September 30, (in millions) 2026 2025 Loss from continuing operations, net of tax, as reported (GAAP) $ (18) $ (6) Income tax (benefit) provision (19) 2 Interest expense, net 38 29 Acquisition-related charges and intangible amortization (1) 5 29 Ex
Slide 12: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Nine Months Ended September 30, (in millions) 2026 2025 Loss from continuing operations, net of tax, as reported (GAAP) $ (113) $ (93) Income tax benefit (27) (1) Interest expense, net 105 79 Acquisition-related charges and intangible amortization (1) 63 67 Transacti
Slide 13: GAAP to Non-GAAP Reconciliations, continued
GAAP to Non-GAAP Reconciliations, continued The following items have been excluded from our non-GAAP financial measures: 1) Acquisition-related charges and intangible amortization for the nine months ended September 30, 2025 includes $22 million of acquisition-related charges related to the terminat